ProKidney

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ProKidney and other ETFs, options, and stocks.

About PROK

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD.

CEO

Bruce Culleton

CEOBruce Culleton

Employees

204

Employees204

Headquarters

Winston-Salem, North Carolina

HeadquartersWinston-Salem, North Carolina

Founded

2015

Founded2015

Employees

204

Employees204

PROK Key Statistics

Market cap

1.33B

Market cap1.33B

Price-Earnings ratio

-7.53

Price-Earnings ratio-7.53

Dividend yield

—

Dividend yield—

Average volume

66.30M

Average volume66.30M

High today

$5.45

High today$5.45

Low today

$4.48

Low today$4.48

Open price

$4.81

Open price$4.81

Volume

17.75M

Volume17.75M

52 Week high

$7.13

52 Week high$7.13

52 Week low

$0.4603

52 Week low$0.4603

PROK News

TipRanks 3d

ProKidney’s Hold Rating: Balancing Promising Phase 2 Results with Future Uncertainties

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on PROK stock, giving a Hold rating yesterday. Don’t Miss TipRanks’ Half-Year Sale Take ad...

Analyst ratings

43%

of 7 ratings

Buy

42.9%

Hold

42.9%

Sell

14.3%

People also own

Based on the portfolios of people who own PROK. This list is generated using Robinhood data, and it’s not a recommendation.